Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer 2023 Meeting
27 sept. 2023 09h05 HE
|
Senti Biosciences, Inc.
- Four abstracts highlight Gene Circuit platforms that enhance the scope, precision, effectiveness, and controllability of oncology cell therapies - - Abstracts include new preclinical data...
Senti Bio to Participate in Upcoming Conferences
26 sept. 2023 16h05 HE
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing a new generation of cell and gene therapies...
Senti Bio to Participate in Upcoming Investor Conferences
05 sept. 2023 08h30 HE
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing a new generation of cell and gene therapies...
Senti Bio Announces Second Quarter 2023 Results and Pipeline Updates
11 août 2023 08h35 HE
|
Senti Biosciences, Inc.
– GeneFab transaction provides access to clinical manufacturing and extends cash runway into Q4 2024 – – IND for SENTI-202, potentially the first Logic Gated CAR-NK treatment for AML, on...
Senti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufacturing Innovation Business Backed by Celadon Partners
10 août 2023 08h35 HE
|
Senti Biosciences, Inc.
– Celadon Partners to acquire Senti’s manufacturing facility and CMC capabilities to establish GeneFab, an independent manufacturing business for cell and gene therapies – – Transaction anticipated...
Senti Bio to Present at the SVB Securities Global Biopharma Conference
01 févr. 2023 16h05 HE
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using...
Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies; Updates Cash Runway Guidance
27 janv. 2023 08h00 HE
|
Senti Biosciences, Inc.
– R&D focus is on lead oncology candidate SENTI-202 for the treatment of AML and other CD33 and/or FLT3 expressing hematologic malignancies, and SENTI-401 to target colorectal cancer and other...
Senti Bio to Present at 41st Annual J.P. Morgan Healthcare Conference
19 déc. 2022 07h55 HE
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using...
Senti Bio Highlights Preclinical Data from Logic-Gated Gene Circuit CAR-NK Cell Therapy SENTI-202 at ASH Annual Meeting and Investor Event
11 déc. 2022 09h00 HE
|
Senti Biosciences, Inc.
– ASH poster presentation summarizes preclinical data from SENTI-202, an off-the-shelf CAR-NK cell therapy candidate engineered with a logic-gated gene circuit and multi-armed with crIL-15, that is...
Senti Bio to Host Investor Event Highlighting SENTI-202 at the 2022 ASH Annual Meeting
23 nov. 2022 07h55 HE
|
Senti Biosciences, Inc.
– Review of new preclinical data and clinical development plan for SENTI-202 in hematologic malignancies; also featuring KOL discussion of treatment landscape and unmet need in AML – – Live and...